JITC's Reading List

JITC HomeAbout JITCRecent ArticlesJITC Editorial Board Highly Accessed ArticlesJITC Digest Follow JITC on X

Final JITC Reading List

By JITC Publications posted 01-16-2025
Dear JITC Readers, The JITC Reading List will no longer be updated. Over the years, we have shared key scientific articles to help researchers, clinicians, and professionals stay informed on the latest advancements in cancer immunotherapy. We appreciate the support of our readers and contributors who have made this initiative a valuable resource for the scientific community. While this initiative has concluded, you can continue to ...
0 comments

December 2024 JITC Reading List: Dr. Eric Tartour

By JITC Publications posted 12-16-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Basic and Translational Cancer Immunology co-Section Editor Dr. Eric Tartour . “Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity” by Pietro Fontana et al Cell (2024) Abstract: Gasdermin-mediated inflammatory cell death (pyroptosis) can activate protective immunity in immunologically ...
0 comments

November 2024 JITC Reading List: Dr. Praveen Bommareddy

By JITC Publications posted 11-15-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Praveen Bommareddy. “DKN-01 in Combination with Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish” by Samuel J Klempner et al J Clin Oncol. (2024) Key component: New novel IO combination approach: IO combinations ...
0 comments

October 2024 JITC Reading List: Dr. Aude Chapuis

By JITC Publications posted 10-14-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Immune Cell Therapies and Immune Cell Engineering co-Section Editor Dr. Aude Chapuis . “ Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors” by Gabriel Espinosa-Carrasco et al Cancer Cell (2024) Abstract: Tumor-specific CD8 + T cells are frequently dysfunctional ...
0 comments

September 2024 JITC Reading List: Dr. Sandra Demaria

By JITC Publications posted 09-17-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Reviews co-Section Editor Dr. Sandra Demaria . “Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy” by Dhan Chand et al Cancer Discov. (2024) Abstract: Conventional immune checkpoint inhibitors (ICI) targeting CTLA-4 elicit durable survival, ...
0 comments

August 2024 JITC Reading List: Dr. Sjoerd H. van der Burg

By JITC Publications posted 08-20-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Deputy Editor-in-Chief Dr. Sjoerd H. van der Burg. “Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity” by Siyuan You et al Cancer Cell (2024) Summary: The tumor microenvironment (TME) has a significant impact on tumor growth and immunotherapy efficacies. ...
0 comments

July 2024 JITC Reading List: Dr. Howard Kaufman

By JITC Publications posted 07-17-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Oncolytic and Local Immunotherapy Section Editor Dr. Howard Kaufman . “Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients” by Divij Mathew et al Science (2024) Abstract: Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. ...
0 comments

June 2024 JITC Reading List: Dr. Claudia Palena

By JITC Publications posted 06-17-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Basic Tumor Immunology co-Section Editor Dr. Claudia Palena . “Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer” by Katey S S Enfield et al Cancer Discov (2024) Abstract: Understanding the role of the tumor microenvironment (TME) in lung ...
0 comments

May 2024 JITC Reading List: Dr. Michael T. Lotze

By JITC Publications posted 05-14-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Incoming Editor-in-Chief Dr. Michael T. Lotze . “Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma” by Bryan D. Choi et al NEJM (2024) Summary: In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, ...
0 comments

April 2024 JITC Reading List: Dr. Marcela Maus

By JITC Publications posted 04-12-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Immune Cell Therapies and Immune Cell Engineering Section Editor Dr. Marcela Maus . “A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells” by Victor Tieu et al Cell (2024) Summary : CRISPR technologies have begun to revolutionize T cell ...
0 comments

March 2024 JITC Reading List: Dr. Jason Luke

By JITC Publications posted 03-18-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translational Cancer Immunotherapy co-Section Editor Dr. Jason Luke . “Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer” by Memon et al Cancer Cell (2024) Summary: Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about ...
0 comments

February 2024 JITC Reading List: Dr. Sebastian Kobold

By JITC Publications posted 02-15-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Case Reports Section Editor Dr. Sebastian Kobold. “T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy” by Ghilardi et al Nat Med (2024) Abstract: We report a T-cell lymphoma (TCL) occurring three months after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin ...
0 comments

January 2024 JITC Reading List: Dr. Robert L. Ferris

By JITC Publications posted 01-16-2024
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Guidelines and Consensus Statements Section Editor Dr. Robert L. Ferris . “Lung tumor–infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response” by Dykema et al Sci Immunol . (2023) Abstract : Regulatory T cells (T reg ) are conventionally viewed as suppressors ...
0 comments

December 2023 JITC Reading List: Dr. Alexandra Snyder

By JITC Publications posted 12-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Immunotherapy Biomarker's co-Section Editor Dr. Alexandra Synder . “The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients” by Freidrich et al Cancer Cell (2023) Abstract : Bispecific T cell engagers (TCEs) have shown promise in the treatment of various ...
0 comments

November 2023 JITC Reading List: Dr. Praveen Bommareddy

By JITC Publications posted 11-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Praveen Bommareddy . Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial by Routy et al Nature Medicine (2023) Combination therapy with immune checkpoint inhibitors has revolutionized treatment for melanoma, but there is still a significant ...
0 comments

October 2023 JITC Reading List: Dr. Kristin Anderson

By JITC Publications posted 10-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Social Media Editor Dr. Kristin Anderson . “An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment” by DePeaux et al J Exp Med (2023) Abstract : While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments ...
0 comments

September 2023 JITC Reading List: Dr. James L. Gulley

By JITC Publications posted 09-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Interim Editor-in-Chief Dr. James L. Gulley . “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma A Meta-Analysis” by Serritella et al JAMA Oncol. (2023) Abstract: Importance – Although the combination of nivolumab plus ipilimumab has unquestionable benefit over nivolumab monotherapy ...
0 comments

August 2023 JITC Reading List: Dr. Eric Tartour

By JITC Publications posted 08-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Basic Tumor Immunology co-Section Editor Dr. Eric Tartour . “CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers” by Bill et al Science (2023) Abstract: Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering ...
0 comments

July 2023 JITC Reading List: Dr. Sandra Demaria

By JITC Publications posted 07-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Reviews co-Section Editor Dr. Sandra Demaria . “The PD-L1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in HNSCC” by Nieto et al J Natl Cancer Inst. (2023) Abstract: The programmed death receptor 1 (PD-1) and ligand (PD-L1) are validated cancer ...
0 comments

June 2023 JITC Reading List: Dr. Douglas McNeel

By JITC Publications posted 06-01-2023
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translation co-Section Editor Dr. Douglas McNeel . “Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance” by Dhivya Sridaran et al Nat Commun . (2022) Abstract: Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies ...
0 comments